AstraZeneca Group plc(AZN)- NYSE
  • Yesterday, 5:03 AM
    • AstraZeneca (NYSE:AZN) will pay $5.5M to resolve a foreign bribery probe into improper payments by its sales and marketing staff to state-employed healthcare officials in China and Russia.
    • The SEC detailed the settlement with AstraZeneca in an order instituting an administrative proceeding arising out of violations of provisions in the Foreign Corrupt Practices Act.
    | Yesterday, 5:03 AM | 1 Comment
  • Wed, Aug. 24, 3:10 AM
    • AstraZeneca (NYSE:AZN) has agreed to sell its small-molecule antibiotics operations to Pfizer (NYSE:PFE) in a transaction that could eventually be worth $1.575B.
    • The deal will allow AstraZeneca to focus on three main therapy areas and realize value "from the strong portfolio of established and late-stage small molecule antibiotics."
    • Pfizer will pay $550M upfront plus $175M in January 2019 and as much as $850M in milestones and sales-related payments.
    • The U.S. company will receive approved antibiotics Merrem, Zinforo and Zavicefta, and clinical-development treatments ATM-AVI and CXL. (PR)
    | Wed, Aug. 24, 3:10 AM | 18 Comments
  • Tue, Aug. 23, 4:52 AM
    • The CFA Society of Minnesota hosts an under-the-radar conference today and tomorrow with a powerful roster of presenting companies.
    • The event was moved to later in the month this year in a development which pushes many of the companies past the quiet period imposed around their earnings releases.
    • Notable names in attendance will include Target (NYSE:TGT), Delta Air Lines (NYSE:DAL), (NASDAQ:STMP), General Mills (NYSE:GIS), Piper Jaffray (NYSE:PJC), Spectrum Brands (NYSE:SPB), 3M (NYSE:MMM), and AstraZeneca (NYSE:AZN).
    | Tue, Aug. 23, 4:52 AM | 5 Comments
  • Mon, Aug. 22, 7:31 AM
    • The FDA designates Phase 3-stage AZD3293 for Fast Track review for the treatment of early Alzheimer's disease (AD). AZD3293 inhibits an enzyme called BACE (beta secretase cleaving enzyme) which plays a key role in the formation of myelin sheaths in peripheral nerve cells. In theory, inhibiting BACE will prevent the accumulation of beta-amyloid and slow the progression of AD.
    • A Phase 2/3 study in early AD, AMARANTH, should be completed in August 2019. The primary endpoint is the change from baseline in Clinical Dementia Rating at Week 104. A second Phase 3, DAYBREAK-ALZ, in patients with mild Alzheimer's dementia should commence this quarter. Its primary endpoint is the change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale Score at Week 78. According to, the estimated final data collection date for the primary endpoint is August 2019. The estimated study completion date is April 2021.
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    • AZD3293 is being co-developed and will be co-commercialized by Eli Lilly (NYSE:LLY) and AstraZeneca (NYSE:AZN) under their 2014 strategic alliance. Lilly leads clinical development, assisted by AstraZeneca's Neuroscience Research and Development Team, while AstraZeneca will be responsible for manufacturing. Both firms will commercialize and will equally share future costs for development and commercialization as well as net revenues after launch.
    • Previously: Lilly and AstraZeneca Alzheimer's candidate advances; AstraZeneca earns $100M milestone (April 8)
    | Mon, Aug. 22, 7:31 AM | 2 Comments
  • Sun, Aug. 21, 6:39 PM
    • Pfizer (NYSE:PFE) is close to a $14B deal to acquire cancer drugmaker Medivation (NASDAQ:MDVN), FT says.
    • The price is about 1/3 higher than Medivation's closing price on Friday.
    • Pfizer would be beating out rivals including Celgene (NASDAQ:CELG), Gilead (NASDAQ:GILD), Sanofi (NYSE:SNY), Merck (NYSE:MRK) and AstraZeneca (NYSE:AZN), who have been pursuing Medivation for months.
    • Medivation has already rejected two "inadequate" bids from Sanofi, the last for $11B ($58/share).
    • Shares of Medivation have more than doubled in the last six months.
    • Medivation makes the leading prostate cancer drug, Xtandi, which is expected to generate $5.7B in annual revenue by 2020.It is also developing an experimental drug called Talazoparib, which is designed to stop tumor cells from multiplying by damaging their DNA.
    • Update: It's official. Pfizer will acquire Medivation for $81.50 a share (~$14B). The deal will be immediately accretive to Pfizer's non-GAAP EPS, adding ~$0.05 in the first full year after the transaction closes, expected by Q4. Its 2016 guidance will be unaffected. The deal will be financed with existing cash. Pfizer will host a conference call this morning at 9:00 am ET to discuss the acquisition.
    | Sun, Aug. 21, 6:39 PM | 92 Comments
  • Wed, Aug. 17, 1:30 PM
    • In-play Medivation (MDVN +2.1%) perks up on modestly higher volume on the news that Merck (MRK -0.3%) has joined Sanofi (SNY -0.5%), Celgene (CELG +0.3%), Gilead Sciences (GILD +1.7%), Pfizer (PFE +0.6%) and AstraZeneca (AZN -0.2%) as potential acquirers.
    • Medivation has already rejected two "inadequate" bids from Sanofi, the last for $11B ($58/share).
    | Wed, Aug. 17, 1:30 PM | 36 Comments
  • Wed, Aug. 10, 12:55 PM
    • AstraZeneca (AZN -1.5%) remains bullish on Moderna Therapeutics as it invests $140M in the latter's preferred stock, increasing AZN's stake to 9%.
    • The companies inked their original collaboration agreement in March 2013 with the aim of developing messenger RNA therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as certain cancers. They inked a new deal in January 2016 focused exclusively in oncology.
    • Previously: AstraZeneca inks collaboration with Moderna Therapeutics in cancer (Jan. 11)
    | Wed, Aug. 10, 12:55 PM
  • Wed, Aug. 10, 8:47 AM
    • AstraZeneca (NYSE:AZN) announces successful results from two clinical trials assessing the expanded use of SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol. Both studies achieved their primary endpoints.
    • Phase 3b RISE assessed the ability of SYMBICORT to reduce exacerbations in 1,219 adult patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD).
    • Phase 3 CHASE 3 evaluated the safety and efficacy of SYMBICORT in 273 asthmatic children aged six to less than 12 years of age.
    • The company will share the complete results from both studies when appropriate. Data from CHASE 3 will be submitted to the FDA as part of its efforts to address the issues cited in a Complete Response Letter (CRL) received in April 2009.
    • SYMBICORT is currently approved in the U.S. for the maintenance treatment adults with COPD and treatment of asthmatic patients at least 12 years old.
    | Wed, Aug. 10, 8:47 AM
  • Tue, Aug. 9, 8:04 AM
    • AstraZeneca (NYSE:AZN) -1.2% premarket after its experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.
    • Hopes for the medicine had already been reduced after it failed in another study for treating a rare cancer of the eye in July 2015.
    | Tue, Aug. 9, 8:04 AM
  • Fri, Aug. 5, 5:42 PM
    • Top gainers, as of 5.25 p.m.: ERI +3.6%. OCUL +3.4%. SWIR +2.5%. AZN +2.5%. LGF +2.2%.
    • Top losers, as of 5.25p.m.: CEMP -3.7%. ETFC -3.0%. LNTH -2.8%. ABB -2.6%. UL -2.3%.
    | Fri, Aug. 5, 5:42 PM
  • Fri, Aug. 5, 11:28 AM
    • AstraZeneca (AZN +1.2%) shoots to a 52-week high, as the failure of Bristol-Myers Squibb's (BMY -16.7%) immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer was viewed by investors as good news for rivals AZN and Merck (MRK +6.7%).
    • Analysts at Leerink, Jefferies and Deutsche Bank say the news increases the potential market opportunity for AZN's combination of durvalumab and tremelimumab.
    • Cancer is the hottest area of research across the drug industry, which some analysts believe could make AZN a takeover target again, with speculation recently turning to Novartis as a bidder.
    | Fri, Aug. 5, 11:28 AM | 1 Comment
  • Fri, Jul. 29, 5:39 PM
    • Top gainers, as of 5.25 p.m.: ESI +2.7%. LYG +2.1%. RDUS +1.9%. GLUU +1.7%.
    • Top losers, as of 5.25p.m.: QGEN -3.6%. MPC -3.1%. CREE -3.0%. AZN -2.8%. BTE -2.7%.
    | Fri, Jul. 29, 5:39 PM | 1 Comment
  • Thu, Jul. 28, 10:02 AM
    • AstraZeneca (AZN +5.8%) is up on average volume amid rumors that Novartis (NVS -0.6%) may have interest in a takeover. The timing could be right. Earlier today, AZN posted tepid Q2 numbers. Sales were down 11%, cash flow from operations down 83% with no earnings.
    | Thu, Jul. 28, 10:02 AM | 2 Comments
  • Thu, Jul. 28, 7:28 AM
    • AstraZeneca (NYSE:AZN) Q2 results ($M): Total Revenues: 5,603 (-11.2%); Product Sales: 5,469 (-6.3%).
    • Sales By Region: U.S.: 1,963 (-16.7%); Europe: 1,249 (-1.0%); Est. ROW: 809 (+3.1%); Japan: 569 (+9.0%); Emerging Markets: 1,448 (+1.0%); China: 610 (+4.6%).
    • Sales By Business: Cardiovascular & Metabolic: 2,168 (-11.6%); Oncology: 848 (+19.9%); Respiratory, Inflammation & Autoimmunity: 1,226 (+0.1%); Infection, Neuroscience & Gastrointestinal: 1,227 (-15.5%).
    • Net Income: (31) (-104.5%); EPS: 0.00 (-100.0%); CF Ops: 181 (-83.2%).
    • Key Product Sales: Crestor: 926 (-29.3%); Symbicort: 803 (-4.6%); Nexium: 562 (-13.1%); Pulmicort: 239 (+3.0%); Seroquel XR: 225 (-14.8%); Brilinta/Brillique: 214 (+48.6%); Faslodex: 211 (+22.7%).
    • Shares are up 2% premarket on light volume.
    | Thu, Jul. 28, 7:28 AM | 1 Comment
  • Thu, Jul. 28, 5:50 AM
    • AstraZeneca (NYSE:AZN): Q2 EPS of $0.83 beats by $0.07.
    • Revenue of $5.6B (-11.3% Y/Y) beats by $40M.
    • Shares +1.05% PM.
    • Press Release
    | Thu, Jul. 28, 5:50 AM | 1 Comment
  • Wed, Jul. 27, 5:30 PM
Company Description
AstraZeneca Plc is a global research-based biopharmaceutical company, which primarily focuses on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. The... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United Kingdom